A multi-institutional phase II trial of consolidation S-1 after concurrent chemoradiotherapy with cisplatin and vinorelbine for locally advanced non-small cell lung cancer.

[1]  J. Shiraishi,et al.  Ethnic Difference in Hematological Toxicity in Patients with Non-small Cell Lung Cancer Treated with Chemotherapy: A Pooled Analysis on Asian versus Non-Asian in Phase II and III Clinical Trials , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  N. Ikeda,et al.  Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Masaaki Kawahara,et al.  Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Keitaro Matsuo,et al.  Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Jose Belderbos,et al.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Saito,et al.  Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer: A Comprehensive Analysis of 26,957 Patients with NSCLC , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  Yukiko Nakamura,et al.  Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer , 2010, International Journal of Clinical Oncology.

[8]  Y. Maehara,et al.  Feasibility study of postoperative adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small cell lung cancer-LOGIK 0601 study. , 2010, Lung cancer.

[9]  M. Endo,et al.  Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer , 2009, British Journal of Cancer.

[10]  Cynthia S. Johnson,et al.  Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Ohmatsu,et al.  Concurrent Chemoradiotherapy with Cisplatin and Vinorelbine for Stage III Non-small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  K. Mori,et al.  Docetaxel Consolidation Therapy Following Cisplatin, Vinorelbine, and Concurrent Thoracic Radiotherapy in Patients with Unresectable Stage III Non-small Cell Lung Cancer , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  Walter J Curran,et al.  Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  N. Saijo,et al.  Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non‐small cell lung cancer , 2004, Cancer science.

[15]  R. Livingston,et al.  Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Kudoh,et al.  Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer , 2001, British Journal of Cancer.

[17]  T. Taguchi,et al.  Conceptual Changes in Cancer Chemotherapy: From an Oral Fluoropyrimidine Prodrug, UFT, to a Novel Oral Fluoropyrimidine Prodrug, S-1, and Low-Dose FP Therapy in Japan , 2000, Investigational New Drugs.

[18]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[19]  C. Balch,et al.  AJCC Cancer Staging Manual. 6th ed , 2002 .